Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice

Overview

Journal Neurol Neuroimmunol Neuroinflamm

Specialty Neurology

Date 2024 Sep 25

PMID 39321395

Authors

Hannah Zhao-Fleming

Mohamed Rezk

Shailee Shah

Pranjal Gupta

Anastasia Zekeridou

Eoin P Flanagan

Sean J Pittock

Andrew McKeon

Divyanshu Dubey

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Paraneoplastic neurologic syndrome (PNS) diagnostic criteria were first proposed in 2004 and updated in 2021. The PNS-CARE score, derived from the updated criteria, is a composite model for assigning likelihood for patients with suspected PNS. In this study, we evaluated the utility and applicability of the 2021 PNS-CARE score and present our PNS cohort.

Methods: This is a retrospective study. We identified Mayo Clinic patients suspected to have PNS (1/2005-12/2020) and collected relevant information including demographics, PNS presentation, and clinical outcomes. Inclusion criteria were the following: (1) patients with a syndrome consistent with PNS and (2) patients with sufficient information available in charts. Exclusion criteria were the following: (1) evaluation only before 2005, (2) patients not evaluated by neurology, (3) presentation after immune checkpoint inhibitors, and (4) syndromes not included in 2021 criteria. All patients were evaluated for the 2021 and 2004 PNS criteria.

Results: We identified 484 patients suspected to have PNS at initial presentation, of whom 212 (44%) were considered to have PNS after completion of evaluation. Among these 212 patients, the most common autoantibodies were PCA1 (Yo)-IgG (17%), KLHL11-IgG (16%), and CRMP5-IgG (14%) and the most common phenotypes were rapidly progressive cerebellar syndrome (29%), brainstem encephalitis (14%), and limbic encephalitis (8%). The 2021 PNS criteria definite/probable categorization (PNS-CARE score ≥ 6) had a sensitivity and specificity of 93% and 100%, respectively, while the 2004 PNS criteria definite categorization had a sensitivity and specificity of 67% and 99%, respectively. We found 15 patients with a PNS-CARE score ≤5 who likely had PNS on our review. The most common presentation among these patients was KLHL11-IgG brainstem encephalitis (7/15, 47%) with likely burned-out testicular tumor.

Discussion: Our study validates the PNS-CARE score. A clearer understanding of typical PNS presentation and common underlying malignancies and autoantibodies can aid in earlier and more accurate diagnosis, which is crucial for downstream clinical decisions. Some patients with an intermediate-risk phenotype do not meet probable/definite criteria despite the presence of high-risk antibodies and/or underlying malignancy.

References

Arino H, Garcia R, Rioseras B, Naranjo L, Martinez-Hernandez E, Saiz A . Frequency and Referral Patterns of Neural Antibody Studies During the COVID-19 Pandemic: Experience From an Autoimmune Neurology Center. Neurol Neuroimmunol Neuroinflamm. 2023; 10(4). PMC: 10265401. DOI: 10.1212/NXI.0000000000200129. View

Pittock S, Lucchinetti C, Parisi J, Benarroch E, Mokri B, Stephan C . Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005; 58(1):96-107. DOI: 10.1002/ana.20529. View

Zekeridou A, Lennon V . Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. Mayo Clin Proc. 2019; 94(9):1865-1878. DOI: 10.1016/j.mayocp.2019.02.003. View

Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A . P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002; 59(5):764-6. DOI: 10.1212/wnl.59.5.764. View

Honnorat J, Antoine J . Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007; 2:22. PMC: 1868710. DOI: 10.1186/1750-1172-2-22. View

Shah S, Vazquez Do Campo R, Kumar N, McKeon A, Flanagan E, Klein C . Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments. Neurology. 2020; 96(4):e632-e639. PMC: 7905784. DOI: 10.1212/WNL.0000000000011218. View

Sasaki H, Kohsaka H . Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018; 28(6):913-921. DOI: 10.1080/14397595.2018.1467257. View

Graus F, Delattre J, Antoine J, Dalmau J, Giometto B, Grisold W . Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75(8):1135-40. PMC: 1739186. DOI: 10.1136/jnnp.2003.034447. View

Sabater L, Saiz A, Dalmau J, Graus F . Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol. 2015; 290:80-3. DOI: 10.1016/j.jneuroim.2015.11.009. View

10.

Dechelotte B, Muniz-Castrillo S, Joubert B, Vogrig A, Picard G, Rogemond V . Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3). PMC: 7136063. DOI: 10.1212/NXI.0000000000000701. View

11.

Budhram A, Dubey D, Sechi E, Flanagan E, Yang L, Bhayana V . Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clin Chem. 2020; 66(12):1496-1509. DOI: 10.1093/clinchem/hvaa254. View

12.

Zekeridou A, Majed M, Heliopoulos I, Lennon V . Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments. Thorac Cancer. 2019; 10(4):1001-1004. PMC: 6449272. DOI: 10.1111/1759-7714.13009. View

13.

Kunchok A, McKeon A, Zekeridou A, Flanagan E, Dubey D, Lennon V . Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clin Proc. 2021; 97(3):547-559. DOI: 10.1016/j.mayocp.2021.07.023. View

14.

Titulaer M, Lang B, Verschuuren J . Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011; 10(12):1098-107. DOI: 10.1016/S1474-4422(11)70245-9. View

15.

Hebert J, Riche B, Vogrig A, Muniz-Castrillo S, Joubert B, Picard G . Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7(6). PMC: 7455315. DOI: 10.1212/NXI.0000000000000883. View

16.

Dalmau J, Tuzun E, Wu H, Masjuan J, Rossi J, Voloschin A . Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61(1):25-36. PMC: 2430743. DOI: 10.1002/ana.21050. View

17.

Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J . Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2009; 9(1):67-76. PMC: 2824142. DOI: 10.1016/S1474-4422(09)70324-2. View

18.

Dubey D, Kryzer T, Guo Y, Clarkson B, Cheville J, Costello B . Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Ann Neurol. 2021; 89(5):1001-1010. DOI: 10.1002/ana.26050. View

19.

Lennon V, Kryzer T, Griesmann G, OSuilleabhain P, Windebank A, Woppmann A . Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995; 332(22):1467-74. DOI: 10.1056/NEJM199506013322203. View

20.

Pelosof L, Gerber D . Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010; 85(9):838-54. PMC: 2931619. DOI: 10.4065/mcp.2010.0099. View